← All trials
NCT07002320
Phase 1/Phase 2Interventional
Trials that are a combination of phases 1 and 2.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 28, 2025
- Primary completion
- Oct 31, 2029
- Completion date
- Oct 31, 2029
- First posted
- Jun 3, 2025
- Last posted
- Jun 6, 2025
- Enrollment
- 78
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of LondonLead sponsor
- Queen's University, BelfastCollaborator
- Syntrix Biosystems, Inc.Collaborator
- University of CambridgeCollaborator
- Janssen Pharmaceutica NVCollaborator
- Royal Marsden Hospital NHS TrustCollaborator
- University of LondonOfficial
- Ospedale S. Giovanni BellinzonaCollaborator
- Ospedale S. Giovanni BellinzonaCollaborator
- Prostate Cancer UKCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.